Related Experiment Video
Updated: Feb 27, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.9K
Targeting EGFRvIII for glioblastoma multiforme
Ju Yang1, Jing Yan1, Baorui Liu1
1The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing 210008, China.
Cancer Letters
|June 27, 2017
Summary
Targeting the EGFR variant III (EGFRvIII) antigen, found exclusively in glioblastoma multiforme (GBM) tumors, shows promise. This review covers preclinical and clinical strategies for this targeted glioblastoma therapy.
Area of Science:
- Neuro-oncology
- Cancer immunology
- Molecular targeted therapy
Background:
- Glioblastoma multiforme (GBM) is an aggressive primary brain tumor with limited treatment options.
- Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific antigen present in 25%-33% of GBM patients.
- Targeting tumor-specific antigens is a key strategy for effective cancer therapy.
Purpose of the Study:
- To review the preclinical and clinical findings of targeting EGFRvIII in glioblastoma multiforme.
- To provide an overview of current therapeutic strategies aimed at EGFRvIII.
Main Methods:
- Literature review of preclinical studies and clinical trials focused on EGFRvIII-targeted therapies for GBM.
- Analysis of various therapeutic modalities including CAR T-cell therapy, vaccines, antibodies, and Bi-specific T Cell Engagers.
Main Results:
- EGFRvIII is a validated target due to its tumor-specific expression in GBM.
- Multiple therapeutic approaches targeting EGFRvIII have demonstrated preclinical efficacy.
- Early clinical investigations are exploring the safety and effectiveness of these targeted therapies.
Conclusions:
- Targeting EGFRvIII represents a promising strategy for glioblastoma treatment.
- Further clinical development of EGFRvIII-targeted therapies is warranted.
- Combination strategies may enhance therapeutic outcomes in GBM.
